Importantly, the combination of these inhibitors shows possible additive side effects [225], with both uveitis and serous retinal detachment having been reported after systemic Dabrafenib (B-Raf inhibitor) and Trametinib (MEK inhibitor) [193]. This evidence concerns the gene BRAF and uveitis.